Therefore, it was hypothesized that SOCS3 as a therapeutic factor may inhibit the proliferation and HIF-1α expression in SCLC cells, which proceeded via the PI3K/Akt signaling pathway instead of the Jak/STAT signaling pathway, which has been the focus of investigation in previous years. Here, AKT1 is linked to small cell lung carcinoma.